skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Radiotherapy Improves Survival in Unresected Stage I-III Bronchoalveolar Carcinoma

Abstract

Purpose: To test the hypothesis that radiotherapy (RT) improves the outcome of patients with unresected, nonmetastatic bronchoalveolar carcinoma (BAC) by performing a population-based analysis within the Surveillance, Epidemiology, and End Results (SEER) registry. Methods and Materials: Inclusion criteria were as follows: patients diagnosed with BAC, Stage I-III, between 2001 and 2007. Exclusion criteria included unknown stage, unknown primary treatment modality, Stage IV disease, and those diagnosed at autopsy. Demographic data, treatment details, and overall survival were retrieved from the SEER database. Survival was analyzed using the Kaplan-Meier method and log-rank test. Results: A total of 6933 patients with Stage I-III BAC were included in the analysis. The median age at diagnosis was 70 years (range, 10-101 years). The majority of patients were diagnosed with Stage I (74.4%); 968 patients (14%) did not undergo surgical resection. Unresected patients were more likely to be older (p < 0.0001), male (p = 0.001), black (p < 0.0001), and Stage III (p < 0.0001). Within the cohort of unresected patients, 300 (31%) were treated with RT. The estimated 2-year overall survival for patients with unresected, nonmetastatic BAC was 58%, 44%, and 27% in Stage I, II, and III, respectively. Factors associated with improved survivalmore » included female sex, earlier stage at diagnosis, and use of RT. Median survival in those not receiving RT vs. receiving RT was as follows: Stage I, 28 months vs. 33 months (n = 364, p = 0.06); Stage II, 18 months vs. not reached (n = 31, nonsignificant); Stage III, 10 months vs. 17 months (n = 517, p < 0.003). Conclusions: The use of RT is associated with improved prognosis in unresected Stage I-III BAC. Less than a third of patients who could have potentially benefited from RT received it, suggesting that the medical specialists involved in the care of these patients underappreciate the importance of RT.« less

Authors:
 [1];  [2];  [1];  [2]; ;  [1];  [3];  [1];  [4];  [3]
  1. Department of Oncology, Sheba Medical Center, Ramat Gan (Israel)
  2. Department of Radiation Oncology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania (United States)
  3. (Israel)
  4. (United States)
Publication Date:
OSTI Identifier:
22149596
Resource Type:
Journal Article
Journal Name:
International Journal of Radiation Oncology, Biology and Physics
Additional Journal Information:
Journal Volume: 84; Journal Issue: 3; Other Information: Copyright (c) 2012 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); Journal ID: ISSN 0360-3016
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; AUTOPSY; CARCINOMAS; DIAGNOSIS; EPIDEMIOLOGY; FEMALES; HYPOTHESIS; LUNGS; MALES; PATIENTS; RADIOTHERAPY; SEX; SURGERY

Citation Formats

Urban, Damien, Mishra, Mark, Onn, Amir, Dicker, Adam P., Symon, Zvi, Pfeffer, M. Raphael, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Lawrence, Yaacov Richard, E-mail: yaacovla@gmail.com, Department of Radiation Oncology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania, and Sackler School of Medicine, Tel Aviv University, Tel Aviv. Radiotherapy Improves Survival in Unresected Stage I-III Bronchoalveolar Carcinoma. United States: N. p., 2012. Web. doi:10.1016/J.IJROBP.2012.01.007.
Urban, Damien, Mishra, Mark, Onn, Amir, Dicker, Adam P., Symon, Zvi, Pfeffer, M. Raphael, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Lawrence, Yaacov Richard, E-mail: yaacovla@gmail.com, Department of Radiation Oncology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania, & Sackler School of Medicine, Tel Aviv University, Tel Aviv. Radiotherapy Improves Survival in Unresected Stage I-III Bronchoalveolar Carcinoma. United States. doi:10.1016/J.IJROBP.2012.01.007.
Urban, Damien, Mishra, Mark, Onn, Amir, Dicker, Adam P., Symon, Zvi, Pfeffer, M. Raphael, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Lawrence, Yaacov Richard, E-mail: yaacovla@gmail.com, Department of Radiation Oncology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania, and Sackler School of Medicine, Tel Aviv University, Tel Aviv. Thu . "Radiotherapy Improves Survival in Unresected Stage I-III Bronchoalveolar Carcinoma". United States. doi:10.1016/J.IJROBP.2012.01.007.
@article{osti_22149596,
title = {Radiotherapy Improves Survival in Unresected Stage I-III Bronchoalveolar Carcinoma},
author = {Urban, Damien and Mishra, Mark and Onn, Amir and Dicker, Adam P. and Symon, Zvi and Pfeffer, M. Raphael and Sackler School of Medicine, Tel Aviv University, Tel Aviv and Lawrence, Yaacov Richard, E-mail: yaacovla@gmail.com and Department of Radiation Oncology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania and Sackler School of Medicine, Tel Aviv University, Tel Aviv},
abstractNote = {Purpose: To test the hypothesis that radiotherapy (RT) improves the outcome of patients with unresected, nonmetastatic bronchoalveolar carcinoma (BAC) by performing a population-based analysis within the Surveillance, Epidemiology, and End Results (SEER) registry. Methods and Materials: Inclusion criteria were as follows: patients diagnosed with BAC, Stage I-III, between 2001 and 2007. Exclusion criteria included unknown stage, unknown primary treatment modality, Stage IV disease, and those diagnosed at autopsy. Demographic data, treatment details, and overall survival were retrieved from the SEER database. Survival was analyzed using the Kaplan-Meier method and log-rank test. Results: A total of 6933 patients with Stage I-III BAC were included in the analysis. The median age at diagnosis was 70 years (range, 10-101 years). The majority of patients were diagnosed with Stage I (74.4%); 968 patients (14%) did not undergo surgical resection. Unresected patients were more likely to be older (p < 0.0001), male (p = 0.001), black (p < 0.0001), and Stage III (p < 0.0001). Within the cohort of unresected patients, 300 (31%) were treated with RT. The estimated 2-year overall survival for patients with unresected, nonmetastatic BAC was 58%, 44%, and 27% in Stage I, II, and III, respectively. Factors associated with improved survival included female sex, earlier stage at diagnosis, and use of RT. Median survival in those not receiving RT vs. receiving RT was as follows: Stage I, 28 months vs. 33 months (n = 364, p = 0.06); Stage II, 18 months vs. not reached (n = 31, nonsignificant); Stage III, 10 months vs. 17 months (n = 517, p < 0.003). Conclusions: The use of RT is associated with improved prognosis in unresected Stage I-III BAC. Less than a third of patients who could have potentially benefited from RT received it, suggesting that the medical specialists involved in the care of these patients underappreciate the importance of RT.},
doi = {10.1016/J.IJROBP.2012.01.007},
journal = {International Journal of Radiation Oncology, Biology and Physics},
issn = {0360-3016},
number = 3,
volume = 84,
place = {United States},
year = {2012},
month = {11}
}